Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Breaks Below Two Hundred Day Moving Average Following Analyst Downgrade

Key Points

• Barclays downgraded Fresenius Medical Care to underweight, and the stock fell below its 200-day moving average, trading as low as $22.53.
• Analyst sentiment is cautious: the consensus rating is “Reduce,” with seven Hold and five Sell ratings and an average price target of $23.42.
• The company narrowly missed quarterly EPS estimates ($0.64 versus $0.65), while revenue of $5.59 billion exceeded forecasts of $5.52 billion.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report)'s stock price passed below its 200-day moving average during trading on Tuesday after Barclays downgraded the stock from an equal weight rating to an underweight rating. The stock has a 200-day moving average of $22.91 and traded as low as $22.53. Fresenius Medical Care AG & Co. KGaA shares last traded at $22.7460, with a volume of 1,396,143 shares changing hands.

Several other analysts have also recently commented on the company. BNP Paribas Exane cut Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 target price on the stock. in a report on Tuesday, July 28th. Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 29th. Sanford C. Bernstein upped their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a "market perform" rating in a research report on Thursday, August 6th. Citigroup reissued a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Seven analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average price target of $23.42.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Hedge funds have recently bought and sold shares of the company. Pzena Investment Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 10.8% in the third quarter. Pzena Investment Management LLC now owns 16,617,575 shares of the company's stock valued at $371,901,000 after buying an additional 1,625,494 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 35.6% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 1,106,400 shares of the company's stock worth $24,761,000 after purchasing an additional 290,200 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% during the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company's stock worth $7,701,000 after buying an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its position in Fresenius Medical Care AG & Co. KGaA by 479.2% during the first quarter. Royal Bank of Canada now owns 216,861 shares of the company's stock valued at $4,893,000 after purchasing an additional 179,418 shares during the last quarter. Finally, Ritholtz Wealth Management grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% in the third quarter. Ritholtz Wealth Management now owns 135,135 shares of the company's stock valued at $3,024,000 after buying an additional 6,732 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Stock Performance

The firm has a market capitalization of $12.11 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 5.40 and a beta of 0.78. The stock's fifty day moving average is $22.33 and its two-hundred day moving average is $22.91. The company has a quick ratio of 0.69, a current ratio of 0.99 and a debt-to-equity ratio of 0.37.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.01). Fresenius Medical Care AG & Co. KGaA had a net margin of 4.23% and a return on equity of 9.08%. The firm had revenue of $5.59 billion during the quarter, compared to analyst estimates of $5.52 billion. On average, analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.23 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co. KGaA is a healthcare company focused on treating people with chronic kidney failure. It provides dialysis care through a global network of treatment centers and supports patients who receive care in clinics or at home. The company also develops and supplies products used in dialysis, including dialysis machines, dialyzers, and related medical equipment and materials. Its services include clinical care and support for healthcare providers involved in kidney treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.